Abstract CT169: Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5)
Xiuning Le(The University of Texas MD Anderson Cancer Center), Mark A. Socinski(Florida Hospital Cancer Institute), Julie R. Brahmer(Johns Hopkins University), Hirva Mamdani(Wayne State University), Jennifer M. Suga(Kaiser Permanente Vallejo Medical Center), Christophe Dooms(Chinese Academy of Medical Sciences & Peking Union Medical College), Alexander I. Spira(Virginia Cancer Specialists), Lyndah Dreiling(Spectrum Pharmaceuticals (United States)), Elaine Shum(NYU Langone’s Laura and Isaac Perlmutter Cancer Center), Hovav Nechushtan(University Medical Center), Jonathan W. Riess(Comprehensive Blood & Cancer Center), John Barrett(National Heart Lung and Blood Institute)
Cited by 9
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k